Ergot-derived dopamine agonists in Parkinson's: Implications of associated adverse events

Abstract

Clinical evidence shows that there is an increased risk of pulmonary fibrosis and cardiac valvulopathy in patients prescribed certain dopamine agonists for the treatment of Parkinson's disease. It is important for Parkinson's disease nurse specialists to understand the clinical implications of these findings, and be able to inform and support patients through the process of changing their drug regimens where required. The professional and regulatory recommendations for switching patients on ergot-derived dopamine agonists to alternative therapies are examined and the clinical implications discussed. Some practical suggestions are provided to help nurses ensure that the potential effects of ergot-derived treatments are communicated to patients and decisions are reached with their acknowledgment and full understanding.